Abstract
The international randomized Champion-Platform trial investigated the use of cangrelor, a novel intravenous inhibitor of the platelet ADP receptor, in patients requiring PCI. Although the occurence of the primary endpoint (a composite of death, myocardical infarction, or revascularization) was not significantly affected by administering cangrelor, the 30-day mortality and the rate of stent thrombosis were significantly lower in the actively treated group.
If the beneficial effect on patient prognosis is confirmed during one-year follow-up of patients of this trial and in subsequent research, cangrelor may become standard treatment during coronary interventions.